What does GlycoNex Incorporation do?

GlycoNex Incorporation (4168.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 4168.TWO's market cap?

GlycoNex Incorporation (4168.TWO) has a market capitalization of approximately $2.56 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 4168.TWO pay a dividend?

Yes — GlycoNex Incorporation (4168.TWO) has a dividend payment history. The most recent payment, frequency, and full history are on the Dividend tab.

Is 4168.TWO profitable?

GlycoNex Incorporation (4168.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

4168.TWO

GlycoNex Incorporation

TWO·Biotechnology · Healthcare

NT$22.75NT$0.05+0.22%

Market capNT$2.56B·Aug 26 5:17 AM UTC

Price Chart

NT$22.75+NT$0.05 (+0.22%)today

−17.03%CAGR −3.67%

Select date range

FromTo

Jun 20, 2012Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

4168.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateFeb 26

Last Report DateDec 31

Reported vs Estimate−NT$0.58

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$22.21M

Net Income−NT$270.39M

Net Margin−1,217.4%

Operating Cash Flow−NT$197.85M

Capital ExpendituresNT$5.21M

Free Cash Flow−NT$203.06M

Return on Equity−31.8%

Return on Invested Capital−4.3%

Net CashNT$87.58M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 4168.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 4168.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 4168.TWO and 80,000+ other tickers.

About GlycoNex Incorporation

GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target…

CEO: Mei-Chun Yang
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 25
Website: www.glyconex.com.tw

Peers

Steminent Biotherapeutics Inc.

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 4168.TWO

What does GlycoNex Incorporation do?: GlycoNex Incorporation (4168.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 4168.TWO's market cap?: GlycoNex Incorporation (4168.TWO) has a market capitalization of approximately $2.56 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 4168.TWO pay a dividend?: Yes — GlycoNex Incorporation (4168.TWO) has a dividend payment history. The most recent payment, frequency, and full history are on the Dividend tab.
Is 4168.TWO profitable?: GlycoNex Incorporation (4168.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.